Novartis AG ADR (NYSE: NVS) has a higher price-to-earnings ratio of 18.66x compared to its average ratio. NVS has 36-month beta value of 0.56. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 9 as “hold,” and 2 as “sell.”
The public float for NVS is 1.90B, and currently, short sellers hold a 0.21% ratio of that float. The average trading volume of NVS on April 02, 2025 was 2.23M shares.
NVS) stock’s latest price update
The stock price of Novartis AG ADR (NYSE: NVS) has plunged by -1.68 when compared to previous closing price of 111.48, but the company has seen a -0.70% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-31 that Basel, March 31, 2025 – Novartis announced today the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for Novartis, effective April 14, 2025. She will continue to report to Vas Narasimhan, M.D., CEO of Novartis and remain on the Executive Committee of Novartis (ECN). Klaus Moosmayer, currently Chief Ethics, Risk & Compliance Officer of Novartis, has decided to leave the company and will step down from the ECN to pursue his next chapter of leadership outside Novartis. The current Ethics Risk & Compliance (ERC) function will move under the leadership of Karen Hale. “Klaus has been integral to building trust with society by solving our legacy compliance topics and putting an ethics, risk and compliance system in place, which is regarded highly internally and externally. The impact he has had on our company, our people and our reputation will be long-lasting,” said Vas Narasimhan, CEO of Novartis. “I want to thank Klaus for his extraordinary leadership since he joined the company and ECN and wish him the very best as he pursues his next chapter. I have confidence that Karen will continue the strong commitment and rigor we have around ethics, risk management and compliance at Novartis.” Karen joined Novartis as Chief Legal Officer in May 2021, bringing almost 30 years of experience in resolving legal and compliance issues in the global pharmaceutical industry. Prior to joining Novartis, she held a succession of senior roles at AbbVie including vice president, deputy general counsel and chief ethics and compliance officer. “I am looking forward to leveraging the strengths of Legal and ERC to best align on risk management across the enterprise and to leading our efforts in ensuring our commitment to ethics, risk management, compliance and integrity remain unwavering,” said Karen Hale. Reflecting on his journey in ERC, Klaus Moosmayer shared, “after joining Novartis in 2018, I leave the company with a strong sense of pride on what we have accomplished together in strengthening our reputation and building a holistic integrated assurance system for Novartis.” Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
NVS’s Market Performance
NVS’s stock has fallen by -0.70% in the past week, with a monthly drop of -0.91% and a quarterly rise of 11.40%. The volatility ratio for the week is 1.48% while the volatility levels for the last 30 days are 1.36% for Novartis AG ADR The simple moving average for the past 20 days is -1.78% for NVS’s stock, with a 0.79% simple moving average for the past 200 days.
NVS Trading at 1.24% from the 50-Day Moving Average
After a stumble in the market that brought NVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.35% of loss for the given period.
Volatility was left at 1.36%, however, over the last 30 days, the volatility rate increased by 1.48%, as shares sank -1.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.39% upper at present.
During the last 5 trading sessions, NVS fell by -0.70%, which changed the moving average for the period of 200-days by +3.85% in comparison to the 20-day moving average, which settled at $111.60. In addition, Novartis AG ADR saw 12.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVS starting from Kowalski Robert William, who proposed sale 6,566 shares at the price of $111.72 back on Aug 12 ’24. After this action, Kowalski Robert William now owns shares of Novartis AG ADR, valued at $733,572 using the latest closing price.
Stock Fundamentals for NVS
Current profitability levels for the company are sitting at:
- 0.28 for the present operating margin
- 0.75 for the gross margin
The net margin for Novartis AG ADR stands at 0.23. The total capital return value is set at 0.2. Equity return is now at value 26.33, with 11.34 for asset returns.
Based on Novartis AG ADR (NVS), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 0.56. The debt to equity ratio resting at 0.71. The interest coverage ratio of the stock is 14.46.
Currently, EBITDA for the company is 20.71 billion with net debt to EBITDA at 0.96. When we switch over and look at the enterprise to sales, we see a ratio of 4.47. The receivables turnover for the company is 5.42for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.04.
Conclusion
To put it simply, Novartis AG ADR (NVS) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
